title: Fistulizing Crohn's disease.
abstract: Fistulas are common in Crohn's disease. A population-based study has shown a cumulative risk of 33% after 10 years and 50% after 20 years. Perianal fistulas were the most common (54%). Medical therapy is the main option for perianal fistula once abscesses, if present, have been drained, and should include antibiotics (both ciprofloxacin and metronidazole) and immunomodulators. Infliximab should be reserved for refractory patients. Surgery is often necessary for internal fistulas.
authors.affiliation: Division of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland. christian.felley@chuv.ch
authors.forename: Christian
authors.initials: C
authors.lastname: Felley
authors.forename: Christian
authors.initials: C
authors.lastname: Mottet
authors.forename: Pascal
authors.initials: P
authors.lastname: Juillerat
authors.forename: Valérie
authors.initials: V
authors.lastname: Pittet
authors.forename: Florian
authors.initials: F
authors.lastname: Froehlich
authors.forename: John-Paul
authors.initials: JP
authors.lastname: Vader
authors.forename: Pierre
authors.initials: P
authors.lastname: Michetti
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Gonvers
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000150:complications* / Q000628:therapy; D013505:Digestive System Surgical Procedures / Q000379:methods; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D011350:Proctocolitis / Q000150:complications / Q000628:therapy; D012003:Rectal Fistula / Q000209:etiology* / Q000628:therapy; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D000069285:Infliximab